Neointimal response to second-generation drug-eluting stents in diabetic patients with de-novo coronary lesions: Intravascular ultrasound study

Hoyoun Won, Tae Soo Kang, Bum Kee Hong, Seunghwan Lee, Dong Woon Jeon, Sung Kee Ryu, Pil Ki Min, Young Won Yoon, Byoung Kwon Lee, Hyuck Moon Kwon, Young Guk Ko, Yangsoo Jang

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objectives The aim of this study was to evaluate the extent of neointimal response after the implantation of a second-generation drug-eluting stent, zotarolimus-eluting stent (ZES-ER, Endeavor Resolute) or everolimus-eluting stent (EES, Xience V), using intravascular ultrasound (IVUS) in diabetic patients. Materials and methods In all, 154 diabetic patients with de-novo coronary lesions were randomized to be implanted with a ZES-ER or EES, and the angiographic follow-up at 9 months combined with a complete IVUS study was available for 96 patients with 101 lesions. Results Baseline demographic and lesion parameters were similar in both groups at index percutaneous coronary intervention. On follow-up angiography, in-stent late lumen loss and minimal lumen diameter were not different between the two groups. On IVUS study, neointimal hyperplasia volume [median (interquartile range): ZES-ER vs. EES; 2.25 mm 3 (0.57-6.25) vs. 1.59 mm 3 (0.45-8.37), P=0.615] and in-stent percentage of volume obstruction [median (interquartile range): ZES-ER vs. EES; 1.16% (0.33-3.61) vs. 0.77% (0.29-4.01), P=0.615] showed similar results between the two groups. Conclusion In diabetic patients, the second-generation drug-eluting stents, ZES-ER and EES, were comparable in inhibiting neointimal proliferation.

Original languageEnglish
Pages (from-to)212-219
Number of pages8
JournalCoronary artery disease
Volume26
Issue number3
DOIs
Publication statusPublished - 2015 Apr 22

Fingerprint

Drug-Eluting Stents
Stents
Percutaneous Coronary Intervention
Hyperplasia
Angiography
Demography

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Won, Hoyoun ; Kang, Tae Soo ; Hong, Bum Kee ; Lee, Seunghwan ; Jeon, Dong Woon ; Ryu, Sung Kee ; Min, Pil Ki ; Yoon, Young Won ; Lee, Byoung Kwon ; Kwon, Hyuck Moon ; Ko, Young Guk ; Jang, Yangsoo. / Neointimal response to second-generation drug-eluting stents in diabetic patients with de-novo coronary lesions : Intravascular ultrasound study. In: Coronary artery disease. 2015 ; Vol. 26, No. 3. pp. 212-219.
@article{2afbcc9c87de468b92333d855474fdd0,
title = "Neointimal response to second-generation drug-eluting stents in diabetic patients with de-novo coronary lesions: Intravascular ultrasound study",
abstract = "Objectives The aim of this study was to evaluate the extent of neointimal response after the implantation of a second-generation drug-eluting stent, zotarolimus-eluting stent (ZES-ER, Endeavor Resolute) or everolimus-eluting stent (EES, Xience V), using intravascular ultrasound (IVUS) in diabetic patients. Materials and methods In all, 154 diabetic patients with de-novo coronary lesions were randomized to be implanted with a ZES-ER or EES, and the angiographic follow-up at 9 months combined with a complete IVUS study was available for 96 patients with 101 lesions. Results Baseline demographic and lesion parameters were similar in both groups at index percutaneous coronary intervention. On follow-up angiography, in-stent late lumen loss and minimal lumen diameter were not different between the two groups. On IVUS study, neointimal hyperplasia volume [median (interquartile range): ZES-ER vs. EES; 2.25 mm 3 (0.57-6.25) vs. 1.59 mm 3 (0.45-8.37), P=0.615] and in-stent percentage of volume obstruction [median (interquartile range): ZES-ER vs. EES; 1.16{\%} (0.33-3.61) vs. 0.77{\%} (0.29-4.01), P=0.615] showed similar results between the two groups. Conclusion In diabetic patients, the second-generation drug-eluting stents, ZES-ER and EES, were comparable in inhibiting neointimal proliferation.",
author = "Hoyoun Won and Kang, {Tae Soo} and Hong, {Bum Kee} and Seunghwan Lee and Jeon, {Dong Woon} and Ryu, {Sung Kee} and Min, {Pil Ki} and Yoon, {Young Won} and Lee, {Byoung Kwon} and Kwon, {Hyuck Moon} and Ko, {Young Guk} and Yangsoo Jang",
year = "2015",
month = "4",
day = "22",
doi = "10.1097/MCA.0000000000000195",
language = "English",
volume = "26",
pages = "212--219",
journal = "Coronary Artery Disease",
issn = "0954-6928",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

Neointimal response to second-generation drug-eluting stents in diabetic patients with de-novo coronary lesions : Intravascular ultrasound study. / Won, Hoyoun; Kang, Tae Soo; Hong, Bum Kee; Lee, Seunghwan; Jeon, Dong Woon; Ryu, Sung Kee; Min, Pil Ki; Yoon, Young Won; Lee, Byoung Kwon; Kwon, Hyuck Moon; Ko, Young Guk; Jang, Yangsoo.

In: Coronary artery disease, Vol. 26, No. 3, 22.04.2015, p. 212-219.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Neointimal response to second-generation drug-eluting stents in diabetic patients with de-novo coronary lesions

T2 - Intravascular ultrasound study

AU - Won, Hoyoun

AU - Kang, Tae Soo

AU - Hong, Bum Kee

AU - Lee, Seunghwan

AU - Jeon, Dong Woon

AU - Ryu, Sung Kee

AU - Min, Pil Ki

AU - Yoon, Young Won

AU - Lee, Byoung Kwon

AU - Kwon, Hyuck Moon

AU - Ko, Young Guk

AU - Jang, Yangsoo

PY - 2015/4/22

Y1 - 2015/4/22

N2 - Objectives The aim of this study was to evaluate the extent of neointimal response after the implantation of a second-generation drug-eluting stent, zotarolimus-eluting stent (ZES-ER, Endeavor Resolute) or everolimus-eluting stent (EES, Xience V), using intravascular ultrasound (IVUS) in diabetic patients. Materials and methods In all, 154 diabetic patients with de-novo coronary lesions were randomized to be implanted with a ZES-ER or EES, and the angiographic follow-up at 9 months combined with a complete IVUS study was available for 96 patients with 101 lesions. Results Baseline demographic and lesion parameters were similar in both groups at index percutaneous coronary intervention. On follow-up angiography, in-stent late lumen loss and minimal lumen diameter were not different between the two groups. On IVUS study, neointimal hyperplasia volume [median (interquartile range): ZES-ER vs. EES; 2.25 mm 3 (0.57-6.25) vs. 1.59 mm 3 (0.45-8.37), P=0.615] and in-stent percentage of volume obstruction [median (interquartile range): ZES-ER vs. EES; 1.16% (0.33-3.61) vs. 0.77% (0.29-4.01), P=0.615] showed similar results between the two groups. Conclusion In diabetic patients, the second-generation drug-eluting stents, ZES-ER and EES, were comparable in inhibiting neointimal proliferation.

AB - Objectives The aim of this study was to evaluate the extent of neointimal response after the implantation of a second-generation drug-eluting stent, zotarolimus-eluting stent (ZES-ER, Endeavor Resolute) or everolimus-eluting stent (EES, Xience V), using intravascular ultrasound (IVUS) in diabetic patients. Materials and methods In all, 154 diabetic patients with de-novo coronary lesions were randomized to be implanted with a ZES-ER or EES, and the angiographic follow-up at 9 months combined with a complete IVUS study was available for 96 patients with 101 lesions. Results Baseline demographic and lesion parameters were similar in both groups at index percutaneous coronary intervention. On follow-up angiography, in-stent late lumen loss and minimal lumen diameter were not different between the two groups. On IVUS study, neointimal hyperplasia volume [median (interquartile range): ZES-ER vs. EES; 2.25 mm 3 (0.57-6.25) vs. 1.59 mm 3 (0.45-8.37), P=0.615] and in-stent percentage of volume obstruction [median (interquartile range): ZES-ER vs. EES; 1.16% (0.33-3.61) vs. 0.77% (0.29-4.01), P=0.615] showed similar results between the two groups. Conclusion In diabetic patients, the second-generation drug-eluting stents, ZES-ER and EES, were comparable in inhibiting neointimal proliferation.

UR - http://www.scopus.com/inward/record.url?scp=84928275422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928275422&partnerID=8YFLogxK

U2 - 10.1097/MCA.0000000000000195

DO - 10.1097/MCA.0000000000000195

M3 - Article

C2 - 25426659

AN - SCOPUS:84928275422

VL - 26

SP - 212

EP - 219

JO - Coronary Artery Disease

JF - Coronary Artery Disease

SN - 0954-6928

IS - 3

ER -